Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?

Toyoda H, Kumada T, Tada T.

J Hepatol. 2013 Apr;58(4):838-9. doi: 10.1016/j.jhep.2012.11.034. Epub 2012 Dec 1. No abstract available.

2.

Reply to: "Lower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: is it really the effect of the therapy?".

Ogawa E, Furusyo N, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Apr;58(4):839-40. doi: 10.1016/j.jhep.2012.11.040. Epub 2012 Dec 2. No abstract available.

3.

Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: further evidence in decompensation cirrhosis.

Ji F, Zhang S, Deng H, Li Z.

J Hepatol. 2013 Jun;58(6):1262-4. doi: 10.1016/j.jhep.2013.01.041. Epub 2013 Feb 7. No abstract available.

4.

Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group.

J Hepatol. 2013 Mar;58(3):495-501. doi: 10.1016/j.jhep.2012.10.017. Epub 2012 Oct 23.

PMID:
23099187
5.

Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.

Honda T, Ishigami M, Masuda H, Ishizu Y, Kuzuya T, Hayashi K, Itoh A, Hirooka Y, Nakano I, Ishikawa T, Urano F, Yoshioka K, Toyoda H, Kumada T, Katano Y, Goto H.

J Gastroenterol Hepatol. 2015 Feb;30(2):321-8. doi: 10.1111/jgh.12703.

PMID:
25091027
6.

[Antiviral treatments during cirrhosis].

Bronowicki JP.

Gastroenterol Clin Biol. 2006 Jun-Jul;30(6-7):899-902. Review. French. No abstract available.

7.

Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.

Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group.

Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1.

8.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
9.

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

Bruix J, Poynard T, Colombo M, Schiff E, Burak K, Heathcote EJ, Berg T, Poo JL, Mello CB, Guenther R, Niederau C, Terg R, Bedossa P, Boparai N, Griffel LH, Burroughs M, Brass CA, Albrecht JK; EPIC3 Study Group.

Gastroenterology. 2011 Jun;140(7):1990-9. doi: 10.1053/j.gastro.2011.03.010. Epub 2011 Mar 17. Erratum in: Gastroenterology. 2013 Oct;145(4):910.

PMID:
21419770
10.

[Effectiveness of long-acting interferon (peginterferon)].

Kondo Y, Tateishi R, Yoshida H, Omata M.

Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):515-8. Review. Japanese. No abstract available.

PMID:
15359853
11.

Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.

Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.

Am J Kidney Dis. 2013 Oct;62(4):789-95. doi: 10.1053/j.ajkd.2013.03.037. Epub 2013 Jun 5.

PMID:
23746377
12.

Treatment of interferon-alpha for chronic hepatitis C.

Moriyama M, Arakawa Y.

Expert Opin Pharmacother. 2006 Jun;7(9):1163-79. Review.

PMID:
16732703
13.

[Improved virologic response in chronic hepatitis C treated with peginterferon, ribavirin and add-on drug].

Hokari A.

Nihon Rinsho. 2011 May;69 Suppl 4:196-200. Review. Japanese. No abstract available.

PMID:
22096918
14.

Assessment of the efficacy of reducing peginterferon alpha-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C.

Kwon JH, Bae SH, Choi JY, Yoon SK, Byun KS, Paik SW, Lim YS, Lee HC, Han KH, Lee KS.

Korean J Intern Med. 2009 Sep;24(3):203-11. doi: 10.3904/kjim.2009.24.3.203. Epub 2009 Aug 26.

15.

The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.

Huang JF, Yu ML, Huang CF, Chiu CF, Dai CY, Huang CI, Yeh ML, Yang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Wang LY, Chuang WL.

J Hepatol. 2011 Feb;54(2):219-26. doi: 10.1016/j.jhep.2010.07.011. Epub 2010 Sep 7.

PMID:
21056500
16.

[Triple therapy with direct acting antiviral agent, peginterferon and ribavirin for chronic hepatitis C].

Izumi N, Kurosaki M, Suzuki S, Tamaki N.

Nihon Shokakibyo Gakkai Zasshi. 2012 Dec;109(12):2108-11. Japanese. No abstract available.

PMID:
23221060
17.

[Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].

Delić D, Mitrović N, Popović N, Urošević A, Pešiċ I, Simonoviċ J.

Srp Arh Celok Lek. 2012 Sep-Oct;140(9-10):612-8. Serbian.

18.

Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin.

Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM.

Hepatology. 2012 Aug;56(2):464-73. doi: 10.1002/hep.25661. Epub 2012 Jun 11.

PMID:
22334369
19.

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.

Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y.

BMC Res Notes. 2012 Mar 10;5:135. doi: 10.1186/1756-0500-5-135.

20.

[Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].

Imamura M, Chayama K.

Nihon Naika Gakkai Zasshi. 2014 Mar 10;103(3):625-9. Review. Japanese. No abstract available.

PMID:
24796128
Items per page

Supplemental Content

Write to the Help Desk